Analyst Ratings For
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)
Today, Cowen reiterated its Buy rating on
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP).
There are 5 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is Buy with a consensus target price of $7.03 per share, a potential 663.59% upside.
Some recent analyst ratings include
- 11/7/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had its Buy rating reiterated by Cowen
- 8/1/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) gets downgraded to Neutral by Guggenheim- 5/31/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has coverage initiated with a Buy rating and $7.00 price target- 5/30/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had its Buy rating reiterated by Citigroup with a $8.00 price target- 5/7/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had its Outperform ➝ Market Perform rating reiterated by Svb Leerink with a $5.00 price target- 5/7/2019-
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) gets downgraded to Market Perform by Leerink Swann with a price target of $4.15Recent Trading Activity for
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)
Shares ofAdaptimmune Therapeutics PLC – ADR closed the previous trading session at with 0.9 shares trading hands. - 8/1/2019-
